National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Diagnostic Study of Cytogenetics in Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Last Modified: 11/21/2009     First Published: 11/1/2002  

Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Published Results
Related Publications
Trial Contact Information
Related Information
Registry Information

Alternate Title

Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
No phase specifiedDiagnosticActive15 and overNCICALGB-8461
NCT00048958

Objectives

  1. Determine the incidence of chromosomal abnormalities in patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, or multiple myeloma.
  2. Correlate specific chromosomal abnormalities with clinical and laboratory parameters in these patients.
  3. Correlate specific karyotype groups with treatment response rates, response duration, survival, and cure in patients treated with various induction and post-induction regimens.
  4. Correlate specific karyotype groups with multidrug resistance data in these patients.
  5. Identify new chromosome abnormalities important in leukemogenesis.
  6. Correlate specific karyotype groups with epidemiological data (toxic exposure and family history) in these patients.
  7. Determine karyotype changes at relapse and the influence of the type of change (or no change) in karyotype at relapse in subsequent clinical courses in these patients.
  8. Correlate specific karyotype groups with selected molecular abnormalities as studied in CALGB leukemia protocols.

Entry Criteria

Disease Characteristics:

  • Must enroll (within 1 month of registration on this study) on a CALGB treatment study for previously untreated acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndromes

  • Patients enrolled on CLB-100001 (previously treated or untreated multiple myeloma) must enroll on this study

  • Simultaneous registration on CLB-9665 (within the continental United States)

Prior/Concurrent Therapy:

Biologic therapy

  • Not specified

Chemotherapy

  • Not specified

Endocrine therapy

  • Not specified

Radiotherapy

  • Not specified

Surgery

  • Not specified

Patient Characteristics:

Age

  • 15 and over

Performance status

  • Not specified

Life expectancy

  • Not specified

Hematopoietic

  • Not specified

Hepatic

  • Not specified

Renal

  • Not specified

Expected Enrollment

6400

Approximately 6,400 patients will be accrued for this study.

Outline

This is a multicenter study.

Patients undergo collection of bone marrow and blood specimens for cytogenetic analysis at diagnosis, complete remission, and relapse. Specimens are karyotyped and examined for chromosomal abnormalities.

Published Results

Farag SS, Archer KJ, Mrózek K, et al.: Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 108 (1): 63-73, 2006.[PUBMED Abstract]

Farag SS, Ruppert AS, Mrózek K, et al.: Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol 23 (3): 482-93, 2005.[PUBMED Abstract]

Bloomfield CD, Ruppert AS, Mrózek K, et al.: Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461. Ann Hematol 83 (Suppl 1): S84-5, 2004.[PUBMED Abstract]

Blum W, Mrozek K, Ruppert AS, et al.: Early allogeneic transplantation for adults with de novo acute myeloid leukemia presenting with t(6;11)(q27;q23): results from CALGB 8461. [Abstract] J Clin Oncol 22 (Suppl 14): A-6543, 568s, 2004.

Blum W, Mrózek K, Ruppert AS, et al.: Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature. Cancer 101 (6): 1420-7, 2004.[PUBMED Abstract]

Byrd JC, Ruppert AS, Mrózek K, et al.: Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol 22 (6): 1087-94, 2004.[PUBMED Abstract]

Farag SS, Archer KJ, Mrózek K, et al.: Pre-treatment cytogenetics predict complete remission and long-term outcome in patients (Pts) ≥60 years with acute myeloid leukemia (AML): results from Cancer and Leukemia Group B (CALGB) 8461. [Abstract] Blood 104 (11): A-568, 2004.

Marcucci G, Mrózek, K, Ruppert AS, et al.: t(8;21) Acute myeloid leukemia (AML) differs from inv(16) AML in pretreatment characteristics, outcome and prognostic factors predicting outcome: a Cancer and Leukemia Group B (CALGB) Study. [Abstract] Blood 104 (11): A-2017, 2004.

Marcucci G, Mrózek K, Ruppert AS, et al.: Association of abnormal cytogenetics at date of morphologic complete remission (CR) with overall (OS), disease-free survival (DFS) and higher relapse rate in acute myeloid leukemia (AML): results from Cancer and Leukemia Group B (CALGB) 8461. [Abstract] J Clin Oncol 22 (Suppl 14): A-6514, 561s, 2004.

Marcucci G, Mrózek K, Ruppert AS, et al.: Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from Cancer and Leukemia Group B study 8461. J Clin Oncol 22 (12): 2410-8, 2004.[PUBMED Abstract]

Slovak ML, Bloomfield CD, Gundacker H, et al.: Acute myeloid leukemia (AML) with t(6;9)(p23;q34) defines a very poor risk leukemia subgroup with distinguishing clinicopathological features: a United States (US) Cytogenetics Intergroup Study of 62 AML and MDS cases. [Abstract] Blood 104 (11): A-567, 2004.

Byrd JC, Mrózek K, Dodge RK, et al.: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100 (13): 4325-36, 2002.[PUBMED Abstract]

Farag SS, Archer KJ, Mrózek K, et al.: Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Int J Oncol 21 (5): 1041-51, 2002.[PUBMED Abstract]

Bloomfield CD, Byrd JC, Farag SS, et al.: Cytogenetics for treatment stratification in adult acute myeloid leukemia (AML). [Abstract] Ann Hematol 80 (Suppl 2): A-37, S10, 2001.

Byrd JC, Mrózek K, Dodge R, et al.: Pre-treatment cytogenetics predict initial induction success and overall survival in adult patients with de novo acute myeloid leukemia: results from CALGB 8461. [Abstract] Blood 98 (11 Pt 1): A-1912, 457a, 2001.

Farag SS, Archer KJ, Carroll AJ, et al.: Isolated trisomy (IT) is an adverse prognostic factor in patients (pts) with AML: results from Cancer and Leukemia Group B (CALGB 8461). [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1124, 2001.

Marcucci G, Archer KJ, Mrózek K, et al.: Abnormal karyotype during complete remission (CR) predicts short relapse-free survival (RFS) in acute myeloid leukemia (AML): results from CALGB 8461. [Abstract] Blood 98 (11 Pt 1): A-2421, 577a, 2001.

Wetzler M, Dodge RK, Mrozek K, et al.: Secondary chromosome aberrations in adult acute lymphoblastic leukemia (ALL) with t(9;22) - a Cancer and Leukemia Group B (CALGB) study. [Abstract] Blood 98 (11 Pt 1): A-466, 111a, 2001.

Wetzler M, Dodge RK, Mrózek K, et al.: Karyotype change in adult acute myeloid leukemia (AML) at first relapse - CALGB 8461. [Abstract] Blood 96 (11 Pt 1): A-3046, 706a, 2000.

Bloomfield D: Adult acute myeloid leukemia (AML) patients (PTS) with t(8;21)(q22;q22) have a superior outcome when repetitive cycles of high-dose cytarabine (HDAC) are administered. [Abstract] Ann Hematol 78 (Suppl 2): A-50, S13, 1999.

Byrd JC, Dodge RK, Carroll A, et al.: Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 17 (12): 3767-75, 1999.[PUBMED Abstract]

Wetzler M, Dodge RK, Mrózek K, et al.: Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood 93 (11): 3983-93, 1999.[PUBMED Abstract]

Baer MR, Stewart CC, Lawrence D, et al.: Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry. Leukemia 12 (3): 317-25, 1998.[PUBMED Abstract]

Bloomfield CD, Lawrence D, Byrd JC, et al.: Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58 (18): 4173-9, 1998.[PUBMED Abstract]

Byrd JC, Dodge R, Carroll A, et al.: Adult acute myeloid leukemia (AML) patients (PTS) with t(8;21)(q22;q22) have a superior outcome when repetitive cycles of high-dose cytarabine (HDAC) are administered. [Abstract] Blood 92 (10 Pt 1): A-1282, 312a, 1998.

Byrd JC, Lawrence D, Arthur DC, et al.: Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461. Clin Cancer Res 4 (5): 1235-41, 1998.[PUBMED Abstract]

Caligiuri MA, Strout MP, Lawrence D, et al.: Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 58 (1): 55-9, 1998.[PUBMED Abstract]

Heinonen K, Mrózek K, Lawrence D, et al.: Clinical characteristics of patients with de novo acute myeloid leukaemia and isolated trisomy 11: a Cancer and Leukemia Group B study. Br J Haematol 101 (3): 513-20, 1998.[PUBMED Abstract]

Wetzler M, Dodge RK, Mrózek K, et al.: Trisomy 8 represents a poor risk group in adult acute lymphoblastic leukemia (ALL): results from Cancer and Leukemia Group B (CALGB) 8461. [Abstract] Blood 92 (10 Pt 1): A-914, 223a, 1998.

Byrd JC, Weiss RB, Arthur DC, et al.: Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol 15 (2): 466-75, 1997.[PUBMED Abstract]

Mrózek K, Heinonen K, Lawrence D, et al.: t(9;11)(p22;q23) confers better prognosis than other translocations of 11q23 in adults with de novo acute myeloid leukemia (AML): a Cancer and Leukemia Group B study. [Abstract] Cytogenet Cell Genet 77: A-P332, 136, 1997.

Mrózek K, Heinonen K, Lawrence D, et al.: Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a Cancer and Leukemia Group B study. Blood 90 (11): 4532-8, 1997.[PUBMED Abstract]

Bernstein SH, Brunetto VL, Davey FR, et al.: Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. J Clin Oncol 14 (9): 2486-94, 1996.[PUBMED Abstract]

Byrd JC, Lawrence D, Arthur DC, et al.: Acute myeloid leukemia (AML) patients with pre-treatment isolated trisomy 8 are rarely cured with chemotherapy: results of CALGB 8461. [Abstract] Proc Am Assoc Cancer Res 37: A-1286, 188, 1996.

Caligiuri MA, Strout MP, Arthur DC, et al.: Rearrangement of ALL1 is a recurrent molecular defect in adult acute myeloid leukemia (AML) with normal cytogenetics that predicts a short complete remission (CR) duration. [Abstract] Proceedings of the American Society of Clinical Oncology 15: A-1060, 1996.

Chen H, Sandler DP, Taylor JA, et al.: Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet 347 (8997): 295-7, 1996.[PUBMED Abstract]

Heinonen K, Mrózek K, Lawrence D, et al.: Trisomy 11 as the sole karyotypic abnormality identifies a group of older patients with acute myeloid leukemia (AML) with FAB M2 or M1 and unfavorable clinical outcome. Results of CALGB 8461. [Abstract] Proc Am Assoc Cancer Res 37: A-1275, 186-7, 1996.

Slack JL, Arthur DC, Lawrence D, et al.: Secondary (2°) cytogenetic changes in acute promyelocytic leukemia (APL): prognostic importance and association with the intron 3 breakpoint of the PML gene. [Abstract] Proc Am Assoc Cancer Res 37: A-3815, 557, 1996.

Related Publications

Marcucci G, Mrózek K, Ruppert AS, et al.: Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 23 (24): 5705-17, 2005.[PUBMED Abstract]

Mrozek K, Carroll AJ, Maharry K, et al.: Central review of cytogenetics is essential for cooperative group clinical and correlative studies of acute leukemia: The Cancer and Leukemia Group B (CALGB) 8461 experience. [Abstract] Blood 104 (11): A-1081, 2004.

Sekeres MA, Peterson B, Dodge RK, et al.: Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood 103 (11): 4036-42, 2004.[PUBMED Abstract]

Baldus CD, Tanner SM, Ruppert AS, et al.: BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood 102 (5): 1613-8, 2003.[PUBMED Abstract]

Heinonen K, Rao PN, Slack JL, et al.: Isochromosome 12p in two cases of acute myeloid leukaemia without evidence of germ cell tumour. Br J Haematol 93 (3): 677-80, 1996.[PUBMED Abstract]

Trial Contact Information

Trial Lead Organizations

Cancer and Leukemia Group B

Clara Bloomfield, MD, Protocol chair
Ph: 614-293-7518
Email: clara.bloomfield@osumc.edu

Trial Sites

U.S.A.
Alabama
  Birmingham
 UAB Comprehensive Cancer Center
 Clinical Trials Office - UAB Comprehensive Cancer Center
Ph: 205-934-0309
California
  La Jolla
 Rebecca and John Moores UCSD Cancer Center
 Clinical Trials Office - Rebecca and John Moores UCSD Cancer Center
Ph: 858-822-5354
 Email: cancercto@ucsd.edu
  Mountain View
 Camino Medical Group - Treatment Center
 Peter Yu, MD
Ph: 408-524-5814
  San Diego
 Kaiser Permanente Medical Office -Vandever Medical Office
 Han Koh
Ph: 619-528-2596
  San Francisco
 UCSF Helen Diller Family Comprehensive Cancer Center
 Clinical Trials Office - UCSF Helen Diller Family Comprehensive Cancer Center
Ph: 877-827-3222
Delaware
  Lewes
 Tunnell Cancer Center at Beebe Medical Center
 Clinical Trials Office - Tunnell Cancer Center
Ph: 302-645-3171
  Newark
 CCOP - Christiana Care Health Services
 Clinical Trial Office - CCOP - Christiana Care Health Services
Ph: 302-733-6227
District of Columbia
  Washington
 Walter Reed Army Medical Center
 Clinical Trials Office - Walter Reed Army Medical Center
Ph: 202-782-7840
Florida
  Fort Lauderdale
 Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
 Clinical Trials Office - Michael and Dianne Bienes Comprehensive Cancer Center
Ph: 954-776-3239
  Jupiter
 Ella Milbank Foshay Cancer Center at Jupiter Medical Center
 Clinical Trials Office - Ella Milbank Foshay Cancer Center
Ph: 561-745-5768
  Miami Beach
 CCOP - Mount Sinai Medical Center
 Rogerio Lilenbaum, MD
Ph: 305-535-3310
  Orlando
 Florida Hospital Cancer Institute at Florida Hospital Orlando
 Clinical Trials Office - Florida Hospital Cancer Institute
Ph: 407-303-5623
  Weston
 Cleveland Clinic Florida - Weston
 Clinical Trials Office - Cleveland Clinic Florida - Weston
Ph: 954-659-5705
Illinois
  Bloomington
 St. Joseph Medical Center
 John Kugler, MD
Ph: 309-243-3605
  Bloomington%
 Illinois CancerCare - Bloomington
 John Kugler, MD
Ph: 309-243-3605
  Canton
 Graham Hospital
 John Kugler, MD
Ph: 309-243-3605
 Illinois CancerCare - Canton
 John Kugler, MD
Ph: 309-243-3605
  Carthage
 Illinois CancerCare - Carthage
 John Kugler, MD
Ph: 309-243-3605
 Memorial Hospital
 John Kugler, MD
Ph: 309-243-3605
  Chicago
 University of Chicago Cancer Research Center
 Clinical Trials Office - University of Chicago Cancer Research Center
Ph: 773-834-7424
 University of Illinois Cancer Center
 Clinical Trial Office - University of Illinois Cancer Center
Ph: 312-355-3046
  Eureka
 Eureka Community Hospital
 John Kugler, MD
Ph: 309-243-3605
 Illinois CancerCare - Eureka
 John Kugler, MD
Ph: 309-243-3605
  Evanston
 Evanston Hospital
 Clinical Trials Office - Evanston Hospital
Ph: 847-570-1381
  Galesburg
 Galesburg Clinic, PC
 John Kugler, MD
Ph: 309-243-3605
 Galesburg Cottage Hospital
 John Kugler, MD
Ph: 309-243-3605
 Illinois CancerCare - Galesburg
 John Kugler, MD
Ph: 309-243-3605
  Havana
 Illinois CancerCare - Havana
 John Kugler, MD
Ph: 309-243-3605
 Mason District Hospital
 John Kugler, MD
Ph: 309-243-3605
  Kewanee
 Illinois CancerCare - Kewanee Clinic
 John Kugler, MD
Ph: 309-243-3605
  Macomb
 Illinois CancerCare - Macomb
 John Kugler, MD
Ph: 309-243-3605
 McDonough District Hospital
 John Kugler, MD
Ph: 309-243-3605
  Monmouth
 Illinois CancerCare - Monmouth
 John Kugler, MD
Ph: 309-243-3605
 OSF Holy Family Medical Center
 John Kugler, MD
Ph: 309-243-3605
  Normal
 BroMenn Regional Medical Center
 John Kugler, MD
Ph: 309-243-3605
 Community Cancer Center
 John Kugler, MD
Ph: 309-243-3605
 Illinois CancerCare - Community Cancer Center
 John Kugler, MD
Ph: 309-243-3605
  Ottawa
 Community Hospital of Ottawa
 John Kugler, MD
Ph: 309-243-3605
 Oncology Hematology Associates of Central Illinois, PC - Ottawa
 John Kugler, MD
Ph: 309-243-3605
  Pekin
 Cancer Treatment Center at Pekin Hospital
 John Kugler, MD
Ph: 309-243-3605
 Illinois CancerCare - Pekin
 John Kugler, MD
Ph: 309-243-3605
  Peoria
 CCOP - Illinois Oncology Research Association
 John Kugler, MD
Ph: 309-243-3605
 Methodist Medical Center of Illinois
 Clinical Trials Office - Methodist Medical Center of Illinois
Ph: 309-243-3000
 Oncology Hematology Associates of Central Illinois, PC - Peoria
 John Kugler, MD
Ph: 309-243-3605
 OSF St. Francis Medical Center
 John Kugler, MD
Ph: 309-243-3605
 Proctor Hospital
 John Kugler, MD
Ph: 309-243-3605
  Peru
 Illinois CancerCare - Peru
 John Kugler, MD
Ph: 309-243-3605
 Illinois Valley Community Hospital
 John Kugler, MD
Ph: 309-243-3605
  Princeton
 Illinois CancerCare - Princeton
 John Kugler, MD
Ph: 309-243-3605
  Rockford
 Center for Cancer Care at OSF Saint Anthony Medical Center
 Clinical Trials Office - Center for Cancer Care at OSF Saint Anthony Medical Center
Ph: 815-227-2633
  Spring Valley
 Illinois CancerCare - Spring Valley
 John Kugler, MD
Ph: 309-243-3605
 St. Margaret's Hospital
 John Kugler, MD
Ph: 309-243-3605
Indiana
  Fort Wayne
 Fort Wayne Medical Oncology and Hematology
 Sreenivasa Nattam, MD
Ph: 260-484-8830
Iowa
  Bettendorf
 Hematology Oncology Associates of the Quad Cities
 Shobha Chitneni, MD, MBBS
Ph: 563-355-7733
  Cedar Rapids
 Iowa Blood and Cancer Care
 David Zenk, MD
Ph: 319-369-7091
 Mercy Regional Cancer Center at Mercy Medical Center
 David Zenk, MD
Ph: 319-369-7091
 St. Luke's Hospital
 David Zenk, MD
Ph: 319-369-7091
  Iowa City
 Holden Comprehensive Cancer Center at University of Iowa
 Cancer Information Service
Ph: 800-237-1225
Kansas
  Overland Park
 Menorah Medical Center
 Rakesh Gaur, MD
Ph: 816-823-0555
 Saint Luke's Hospital - South
 Rakesh Gaur, MD
Ph: 816-823-0555
  Shawnee Mission
 Shawnee Mission Medical Center
 Rakesh Gaur, MD
Ph: 816-823-0555
Maine
  Bangor
 CancerCare of Maine at Eastern Maine Medical Center
 Clinical Trials Office - CancerCare of Maine
Ph: 207-973-4274
  Lewiston
 Central Maine Comprehensive Cancer Center at Central Maine Medical Center
 Ann Traynor
Ph: 207-795-2440
  Scarborough
 Maine Center for Cancer Medicine and Blood Disorders - Scarborough
 Helen Ryan
Ph: 207-885-7600
Maryland
  Baltimore
 Greenebaum Cancer Center at University of Maryland Medical Center
 Clinical Trials Office - Greenebaum Cancer Center at University of Maryladn Medical Center
Ph: 800-888-8823
 Harry & Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center
 Clinical Trials Office - Harry & Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center
Ph: 443-777-7364
  Elkton MD
 Union Hospital Cancer Program at Union Hospital
 Frank Beardell, MD
Ph: 302-737-7700
Massachusetts
  Boston
 Dana-Farber/Brigham and Women's Cancer Center
 Clinical Trials Office
Ph: 617-724-5200
 Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
 Richard Stone, MD
Ph: 617-632-2214
 Massachusetts General Hospital
 Clinical Trials Office - Massachusetts General Hospital
Ph: 877-726-5130
Michigan
  Battle Creek
 Battle Creek Health System Cancer Care Center
 Martin Bury
Ph: 616-966-8000
  Big Rapids
 Mecosta County Medical Center
 Martin Bury
Ph: 231-796-8691
  Grand Rapids
 Butterworth Hospital at Spectrum Health
 Martin Bury
Ph: 616-391-2799
 CCOP - Grand Rapids
 Martin Bury
Ph: 616-391-1230
 Lacks Cancer Center at Saint Mary's Health Care
 Martin Bury
Ph: 616-752-5222
  Muskegon
 Mercy General Health Partners
 Martin Bury
Ph: 231-672-2000
  Saint Joseph
 Oncology Care Associates, PLLC
 Eric Lester, MD
Ph: 269-985-0029
  Traverse City
 Munson Medical Center
 Martin Bury
Ph: 231-935-6202
  Wyoming
 Metro Health Hospital
 Martin Bury
Ph: 616-252-7200
Minnesota
  Duluth
 St. Luke's Hospital Cancer Care Center
 Tanya Repka, MD, FACP
Ph: 218-726-3081
  Minneapolis
 Masonic Cancer Center at University of Minnesota
 Clinical Trials Office - Masonic Cancer Center at University of Minnesota
Ph: 612-624-2620
 Veterans Affairs Medical Center - Minneapolis
 Clinical Trials Office - Veterans Affairs Medical Center - Minneapolis
Ph: 612-467-2800
Missouri
  Columbia
 Ellis Fischel Cancer Center at University of Missouri - Columbia
 Clinical Trial Office - Ellis Fischel Cancer Center
Ph: 573-882-7440
 Missouri Cancer Associates
 Clinical Trials Office - Missouri Cancer Associates
Ph: 866-724-2413
 Email: research@missouricancer.com
  Kansas City
 CCOP - Kansas City
 Rakesh Gaur, MD
Ph: 816-823-0555
 North Kansas City Hospital
 Rakesh Gaur, MD
Ph: 816-823-0555
 Parvin Radiation Oncology
 Rakesh Gaur, MD
Ph: 816-823-0555
 Research Medical Center
 Rakesh Gaur, MD
Ph: 816-823-0555
 Saint Luke's Cancer Institute at Saint Luke's Hospital
 Rakesh Gaur, MD
Ph: 816-823-0555
 St. Joseph Medical Center
 Rakesh Gaur, MD
Ph: 816-823-0555
 Truman Medical Center - Hospital Hill
 Rakesh Gaur, MD
Ph: 816-823-0555
  Lee's Summit
 Saint Luke's East - Lee's Summit
 Rakesh Gaur, MD
Ph: 816-823-0555
  Liberty
 Liberty Hospital
 Rakesh Gaur, MD
Ph: 816-823-0555
  Saint Joseph
 Heartland Regional Medical Center
 Rakesh Gaur, MD
Ph: 816-823-0555
  Saint Louis
 Arch Medical Services, Incorporated at Center for Cancer Care and Research
 Alan Lyss, MD
Ph: 314-996-5514
 Missouri Baptist Cancer Center
 Alan Lyss, MD
Ph: 314-996-5514
 Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
 Nancy Bartlett, MD
Ph: 314-362-5654
Nebraska
  Grand Island
 Saint Francis Cancer Treatment Center at Saint Francis Memorial Health Center
 Lori Maness, MD
Ph: 402-559-5520
  North Platte
 Callahan Cancer Center at Great Plains Regional Medical Center
 Clinical Trials Office - Callahan Cancer Center at Great Plains Regional Medical Center
Ph: 308-696-7864
  Omaha
 Methodist Estabrook Cancer Center
 Robert Langdon, MD
Ph: 402-399-8762
 UNMC Eppley Cancer Center at the University of Nebraska Medical Center
 Clinical Trials Office - UNMC Eppley Cancer Center at the University of Nebraska Medical Center
Ph: 800-999-5465
Nevada
  Las Vegas
 CCOP - Nevada Cancer Research Foundation
 John Ellerton, MD, CM
Ph: 702-384-0013
 University Medical Center of Southern Nevada
 John Ellerton, MD, CM
Ph: 702-384-0013
New Hampshire
  Lebanon
 Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
 Clinical Trials Office - Norris Cotton Cancer Center
Ph: 603-650-7609
 Email: cancerhelp@dartmouth.edu
New Jersey
  Voorhees
 Cancer Institute of New Jersey at Cooper - Voorhees
 Clinical Trials Office - Cancer Institute of New Jersey at Cooper University Hospital - Voorhees
Ph: 856-325-6757
New York
  Buffalo
 Roswell Park Cancer Institute
 Clinical Trials Office - Roswell Park Cancer Institute
Ph: 877-275-7724
  East Syracuse
 CCOP - Hematology-Oncology Associates of Central New York
 Jeffrey Kirshner, MD
Ph: 315-472-7504
  Glens Falls
 Charles R. Wood Cancer Center at Glens Falls Hospital
 Clinical Trials Office - Charles R. Wood Cancer Center at Glens Falls Hospital
Ph: 518-926-6700
  Jamaica
 Queens Cancer Center of Queens Hospital
 Lewis Silverman, MD
Ph: 212-241-5520
  Lake Success
 Monter Cancer Center of the North Shore-LIJ Health System
 Vincent Vinciguerra, MD
Ph: 516-734-8954
  Manhasset
 CCOP - North Shore University Hospital
 Vincent Vinciguerra, MD
Ph: 516-734-8954
 Don Monti Comprehensive Cancer Center at North Shore University Hospital
 Clinical Trials Office - Don Monti Comprehensive Cancer Center at North Shore University Hospital
Ph: 516-734-8900
  New Hyde Park
 Long Island Jewish Medical Center
 Kanti Rai, MD
Ph: 718-470-7135
  New York
 Mount Sinai Medical Center
 Lewis Silverman, MD
Ph: 212-241-5520
 New York Weill Cornell Cancer Center at Cornell University
 Clinical Trials Office - New York Weill Cornell Cancer Center at Cornell University
Ph: 212-746-1848
  Stony Brook
 Stony Brook University Cancer Center
 Clinical Trials Office - Stony Brook University Cancer Center
Ph: 800-862-2215
  Syracuse
 SUNY Upstate Medical University Hospital
 Clinical Trials Office - SUNY Upstate Medical University Hospital
Ph: 315-464-5476
 Veterans Affairs Medical Center - Syracuse
 Jane Hudson
Ph: 315-425-4400
800-792-4334
North Carolina
  Asheville
 Mission Hospitals - Memorial Campus
 Clinical Trials Office - Mission Hospitals - Memorial Campus
Ph: 828-213-4150
  Chapel Hill
 Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
 Clinical Trials Office - Lineberger Comprehensive Cancer Center
Ph: 877-668-0683; 919-966-4432
  Charlotte
 Blumenthal Cancer Center at Carolinas Medical Center
 Clinical Trials Office - Blumenthal Cancer Center at Carolinas Medical Center
Ph: 704-355-2884
 Presbyterian Cancer Center at Presbyterian Hospital
 Clinical Trials Office - Presbyterian Cancer Center at Presbyterian Hospital
Ph: 704-384-5369
  Concord
 Batte Cancer Center at Northeast Medical Center
 James Wall, MD
Ph: 704-783-1370
  Durham
 Duke Comprehensive Cancer Center
 Clinical Trials Office - Duke Comprehensive Cancer Center
Ph: 888-275-3853
  Gastonia
 CaroMont Cancer Center at Gaston Memorial Hospital
 Clinical Trials Office - CaroMont Cancer Center at Gaston Memorial Hospital
Ph: 704-834-2932
  Goldsboro
 Wayne Memorial Hospital, Incorporated
 James Atkins, MD
Ph: 919-580-0000
  Greenville
 Leo W. Jenkins Cancer Center at ECU Medical School
 Clinical Trials Office - Leo W. Jenkins Cancer Center at ECU Medical School
Ph: 252-744-2391
  Henderson
 Maria Parham Medical Center
 Jeffrey Crawford, MD
Ph: 919-681-9509
  Hendersonville
 Pardee Memorial Hospital
 James Radford, MD
Ph: 828-692-8045
  Kinston
 Kinston Medical Specialists
 Peter Watson, MD
Ph: 252-559-2200ext.201
  Lumberton
 Southeastern Regional Medical Center
 Jeffrey Crawford, MD
Ph: 919-681-9509
  Oxford
 Granville Medical Center
 Jeffrey Crawford, MD
Ph: 919-681-9509
  Raleigh
 Duke Health Raleigh Hospital
 Jeffrey Crawford, MD
Ph: 919-681-9509
  Roxboro
 Person Memorial Hospital
 Jeffrey Crawford, MD
Ph: 919-681-9509
  Winston-Salem
 Forsyth Regional Cancer Center at Forsyth Medical Center
 Clinical Trials Office - Forsyth Regional Cancer Center at Forsyth Medical Center
Ph: 336-277-8887
 Wake Forest University Comprehensive Cancer Center
 Clinical Trials Office - Wake Forest University Comprehensive Cancer Center
Ph: 336-713-6771
Ohio
  Columbus
 Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
 Ohio State University Cancer Clinical Trial Matching Service
Ph: 866-627-7616
 Email: osu@emergingmed.com
Oklahoma
  Oklahoma City
 Cancer Care Associates - Mercy Campus
 Howard Ozer, MD, PhD
Ph: 405-271-4022
 Oklahoma University Cancer Institute
 Howard Ozer, MD, PhD
Ph: 405-271-4022
Pennsylvania
  Pittsburgh
 Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
 John Lister
Ph: 412-578-5000
Rhode Island
  Pawtucket
 Memorial Hospital of Rhode Island
 Humera Khurshid
Ph: 401-729-2000
  Providence
 Miriam Hospital
 Clinical Trials Office - Miriam Hospital
Ph: 401-793-2224
 Rhode Island Hospital Comprehensive Cancer Center
 Clinical Trials Office - Rhode Island Hospital Comprehensive Cancer Center
Ph: 401-444-1488
South Carolina
  Florence
 McLeod Regional Medical Center
 Clinical Trials Office - McLeod Regional Medical Center
Ph: 843-679-7256
  Greenville
 CCOP - Greenville
 Jeffrey Giguere, MD, FACP
Ph: 864-987-7000
Vermont
  Berlin
 Mountainview Medical
 Barbara Grant, MD
Ph: 802-847-8400
  Burlington
 Fletcher Allen Health Care - University Health Center Campus
 Clinical Trials Office - Fletcher Allen Health Care
Ph: 802-656-8990
Virginia
  Danville
 Danville Regional Medical Center
 Clinical Trials Office - Danville Regional Medical Center
Ph: 434-799-3753
  Richmond
 Virginia Commonwealth University Massey Cancer Center
 Clinical Trials Office -Virginia Commonwealth University Massey Cancer Center
Ph: 804-628-1939

Related Information

PDQ® clinical trial CALGB-100001 1

Registry Information
Official Title Cytogenetic Studies For Previously Untreated AML, ALL or MDS Patients (Companion To CALGB Treatment Studies For Previously Untreated AML, ALL Or MDS Patients)
Trial Start Date 1984-06-22
Trial Completion Date 2005-07-02 (estimated)
Registered in ClinicalTrials.gov NCT00048958 2
Date Submitted to PDQ 2002-07-11
Information Last Verified 2009-11-21
NCI Grant/Contract Number CA31946

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.



Table of Links

1http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=69109&version=he
althprofessional
2http://clinicaltrials.gov/ct/show/NCT00048958